The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| REVB | -95.83% | -100% | -93.29% | -100% |
| S&P | +13.02% | +80.03% | +12.46% | +92% |
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.
No news articles found for Revelation Biosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$6.77K | 6.3% |
| Market Cap | $3.32M | -9.1% |
| Market Cap / Employee | $369.09K | 0.0% |
| Employees | 9 | 0.0% |
| Net Income | -$1,907.18K | 14.9% |
| EBITDA | -$1,936.24K | -8.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.71M | 94.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -82.96% | 65.1% |
| Return On Invested Capital | 2139.62% | -83.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,588.90K | 82.9% |
| Operating Free Cash Flow | -$1,588.90K | 82.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.82 | 0.88 | 0.90 | 0.57 | -58.35% |
| Price to Tangible Book Value | 35.53 | 0.88 | 0.75 | 0.57 | -99.03% |
| Enterprise Value to EBITDA | 2.26 | 0.55 | 1.37 | 4.62 | 94.31% |
| Return on Equity | -264.9% | -233.3% | -340.8% | -118.9% | -55.98% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
